S&P 500 Healthcare Sector SPDR (XLV)

Despite Agilent Technologies’ strong performance relative to the broader market over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Vertex Pharmaceuticals has raced ahead of the market, while analysts continue to give the stock a decidedly optimistic outlook.

Veeva Systems has underperformed the broader market amid softer demand and competition, while analysts remain moderately optimistic about its future prospects.

While Incyte has outperformed the broader market over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Thermo Fisher Scientific has underperformed the broader market over the past year, yet analysts remain highly bullish about the stock’s prospects.

Despite DexCom’s weak performance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Although Danaher has underperformed relative to the broader market over the past year, Wall Street analysts maintain a bullish outlook about the stock’s prospects.

Cencora has underperformed the broader market over the past year, yet analysts remain highly bullish about the stock’s prospects.

Though Edwards Lifesciences has underperformed the broader market over the past year, Wall Street analysts maintain a strongly optimistic outlook on the stock’s prospects.

Though DaVita has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.